Price$263.26-3.09 (-1.16%)
01:30 PM07:45 PM
News · 26 weeks129-57%
2026-01-112026-07-05
Mix5490d
- Other31(57%)
- Insider14(26%)
- SEC Filings5(9%)
- Earnings2(4%)
- Dividends1(2%)
- Leadership1(2%)
Latest news
25 items- PRJohnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF PlatformDual Energy THERMOCOOL SMARTTOUCH SF Platform brings pulse field and radiofrequency energy together in a single catheter. Integrated with the CARTO ecosystem, the platform gives physicians greater versatility to tailor treatment based on patient anatomy and case complexity.i Johnson & Johnson (NYSE:JNJ) today announced that the U.S. Food and Drug Administration (FDA) approved the Dual Energy THERMOCOOL SMARTTOUCH SF Platform (DE STSF), an integrated catheter ablation solution that enables electrophysiologists to deliver both radiofrequency (RF) and pulsed field (PF) energy through a single catheter.i This press release features multimedia. View the full release here: https://www.bu
- PRMulti-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge OpportunityNEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients relied on traditional antidepressants that often took several weeks to start working—and didn't always help everyone. Today, drug developers are introducing a new wave of treatments designed to work faster, target different areas of the brain, and offer hope to people with treatment-resistant depression. Researchers are also exploring innovative approaches, including NMDA receptor therapies, orexin-targeting drugs, and other next-generation medicines that could significantly improve patient o
- PRJohnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravisNew analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including those early in their disease, participants with lower symptom burden and those who experienced common infectionsTo address an important evidence gap, the PETUNIAc study design will be presented – demonstrating the innovative way pregnancy outcomes data will be collected following treatment with IMAAVY IMAAVY, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with generalized myasthenia gravis (gMG)GENEVA, June 26, 2026 /PRNew
- SECSEC Form 11-K filed by Johnson & Johnson11-K - JOHNSON & JOHNSON (0000200406) (Filer)
- SECSEC Form 11-K filed by Johnson & Johnson11-K - JOHNSON & JOHNSON (0000200406) (Filer)
- PRJohnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, FloridaInvestment includes new advanced manufacturing and packaging technologies and a new state-of-the-art distribution facility to scale the Company's U.S. Vision operations, enhance supply chain resilience, and meet the needs of more than 40 million patients Investment is part of the Company's ongoing $55 billion commitment to U.S. manufacturing, research and development, and technology through early 2029 Building on more than 40 years of leadership in Florida, the investment supports 3,500 Jacksonville employees and strengthens Johnson & Johnson's $6 billion annual economic impact across the state Johnson & Johnson (NYSE:JNJ) (the "Company"), healthcare's leading, most comprehensive
- PRNew TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myelomaTALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the third positive study in recent months from Johnson & Johnson's bispecific portfolio and is the first Phase 3 study of a GPRC5D bispecific investigational combinationResults reinforce Johnson & Johnson's leadership in multiple myeloma, advancing bispecific combinations earlier in the treatment journey, and expanding options to match the right treatment to the right patient and stage of diseaseSTOCKHOLM, June 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announc
- INSIDEREVP, Chief TO and Risk Officer Wengel Kathryn E exercised 10,000 shares at a strike of $115.67 and sold $2,411,500 worth of shares (10,000 units at $241.15) (SEC Form 4)4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- INSIDERSEC Form 4 filed by Director Woods Eugene A.4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- PRJohnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and PatientsExpanded U.S. availability paired with new patient lifestyle quiz encourages informed decision-making ahead of cataract surgery. Cataracts are one of the leading causes of vision impairment.1 Nearly 20% of Americans aged 40+ live with cataracts that make everyday tasks more challenging, yet only 5% have had cataract surgery.2 Over half a million eyes worldwide have already experienced clearer, extended range of vision with TECNIS PureSee IOL after cataract surgery.3,4 97% of patients would recommend TECNIS PureSee IOL to friends or family.5 Johnson & Johnson (NYSE:JNJ) is expanding the U.S. roll-out of its latest advancement in presbyopia-correcting intraocular lenses (PC-IOLs)
- PRIMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapiesPatients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as early as Week 1c More patients treated with IMAAVY experienced improvement in fatigued and corticosteroid dose reductionse IMAAVY is designed to target pathogenic immunoglobulin G (IgG) autoantibodies in warm autoimmune hemolytic anemia while preserving immune function Pivotal results will be presented at EHA 2026 STOCKHOLM, June 11, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today is presenting the first comprehensive results from the Phase 2/3 ENERGY study showing that IMAAVY® (nipocalimab-aahu) produced a statistica
- PRJohnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos TrialDean Omar Branham Shirley secures verdict on behalf of family of woman who died from mesothelioma A Los Angeles jury has awarded $32 million to the family of a California woman who died from pleural mesothelioma after years of exposure to an asbestos-contaminated talc product, finding Johnson & Johnson (NYSE:JNJ) and its subsidiaries liable for her illness. Maria Lozano died from mesothelioma in 2024. Her children, John Lozano, Araceli Lenard-Lozano and Jeanette Lozano, continued the lawsuit after her death. View the verdict form and photos here. During the trial, the family's attorneys showed how Ms. Lozano regularly used Johnson & Johnson's talc-based baby powder on herself and he
- PRJohnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate PlatformExpands the Company's expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation Johnson & Johnson (NYSE:JNJ) today announced it has entered into a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink™ degrader antibody conjugate (DAC) platform, for $1 billion in cash. The Firelink™ DAC platform for KRAS-driven tumors bolsters Johnson & Johnson's oncology pipeline and ambition
- PRJohnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's diseaseNipocalimab, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with Sjögren's disease while preserving immune function New exploratory analysis of Phase 2 study data shows a strong correlation between autoantibody levels and even greater clinical response rates of participants in the nipocalimab treatment group Previously reported data from the Phase 2 study showed nipocalimab reduced Sjögren's disease activity and severity, with potential to address systemic manifestations and the most burdensome patient-reported symptoms including dryness, fatigue and painNipocalimab is the only FcRn blocker
- PRJohnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigmPatients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20% reduction in the risk of developing metastasis or death Data selected to open the plenary presentation at ASCO 2026 and published in The New England Journal of MedicineCHICAGO, May 31, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus hormone therapy (androgen deprivation therapy, ADT), given for six months before and after prostate cancer surgery, significantly improved key short- and long-term clinical outcomes for patients with high-risk localized
- PRRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancerMedian overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated diseaseConsistent responses observed across atypical EGFR mutation subgroups, including those historically associated with poorer outcomesASCO 2026 results reinforce the significance of RYBREVANT®-based regimens for patients across EGFR mutationsCHICAGO, May 29, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced updated results from the Phase 1/1b CHRYSALIS-2 study evaluating intravenous RYBREVANT® (amivantamab-vmjw) in combination with LAZCLUZE® (lazertinib) in patients with advanced non-small cell lung cancer (NSCLC) with atypica
- PRNew TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myelomaBuilding on the recent approval of Johnson & Johnson's TECVAYLI® plus DARZALEX FASPRO®, MajesTEC-9 is the second positive Phase 3 study to reinforce the strength of TECVAYLI® as early as second line TECVAYLI® delivered deep and durable responses with nearly two-thirds of patients achieving a complete response or betterCHICAGO, May 29, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-9 study demonstrating clinically meaningful and statistically significant improvements in progression-free survival (PFS) and overall survival (OS) with TECVAYLI® (teclistamab-cqyv) versus standard of care regim
- PRFDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damageTREMFYA® showed significant inhibition of structural joint damage in adults with active psoriatic arthritisHORSHAM, Pa., May 28, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to include evidence in the TREMFYA® (guselkumab) label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA). The inclusion of this key outcome reflects that TREMFYA is the only IL-23 inhibitor proven to help stop further structural damage, offering patients with active PsA a first-line treatment option that provides effective symptom
- PRJohnson & Johnson to Host Investor Conference Call on Second-Quarter ResultsJohnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 15th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Ryan Koors, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the w
- SECSEC Form SD filed by Johnson & JohnsonSD - JOHNSON & JOHNSON (0000200406) (Filer)
- SECSEC Form 13F-HR filed by Johnson & Johnson13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)
- PRCNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense ResearchAUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Among the most guarded structures in human biology, the brain is also one of the hardest to treat. The blood-brain barrier (BBB), a specialized biological membrane, shields neural tissue from foreign substances, including most therapeutic agents. As cases of Alzheimer's disease climb worldwide and governments sharpen their focus on biodefense, the absence of efficient pathways for delivering drugs to the brain is fast becoming one of medicine's most pressing unresolved problems. Companies such as Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile) are responding to this challenge with next-generation delivery pla
- ANALYSTJohnson & Johnson upgraded by Leerink Partners with a new price targetLeerink Partners upgraded Johnson & Johnson from Market Perform to Outperform and set a new price target of $265.00
- PRJohnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceJohnson & Johnson (NYSE:JNJ) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9th, 2026. Management will participate in a Fireside Chat at 10:00 a.m. Eastern Time. This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com. The audio webcast replay will be available approximately 48 hours after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20260511295368/en/ Media contact: media-relations@its.jnj.com Investor contact: investor-relations@its.jnj.com
- PRJohnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCPOral presentations feature CAPLYTA® long-term data assessing relapse risk reduction in schizophrenia and new seltorexant analyses in major depressive disorder (MDD) with insomnia symptoms18 abstracts highlight J&J's leadership and deep portfolio in neuropsychiatry at the American Psychiatric Association (APA) and American Society of Clinical Psychopharmacology (ASCP) Annual MeetingsTITUSVILLE, N.J., May 11, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that 18 abstracts featuring new and encore data from the Company's robust neuropsychiatry portfolio and pipeline will be presented at two upcoming scientific meetings: the American Psychiatric Association (APA) Annual Meeti
JNJ FAQ
7 questionsWhat does Johnson & Johnson do?
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL...Where does JNJ stock trade?
Johnson & Johnson (JNJ) is listed on NYSE.What sector and industry is JNJ in?
Johnson & Johnson operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.Does JNJ pay a dividend?
JNJ's most recent ex-dividend date was 2026-05-26 with a cash dividend of $1.34 per share. No future ex-date is on file yet.What are analysts saying about JNJ?
Johnson & Johnson has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform on 2026-05-13.What companies are similar to JNJ?
Notable peers in the same industry include AZN (AstraZeneca PLC), MRK (Merck & Company Inc.), NVS (Novartis AG), PFE (Pfizer Inc.), UL (Unilever PLC). Compare JNJ side-by-side with any of them on Quantisnow.How can I track JNJ on Quantisnow?
Quantisnow aggregates Johnson & Johnson's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow JNJ to receive live email and push alerts on every new disclosure.